Nuvation Bio Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Nuvation Bio Inc. (NUVB) reported Revenue from Contract with Customer, Excluding Assessed Tax of $31.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Nuvation Bio Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $31.69M, a 555.64% increase year-over-year.
- Nuvation Bio Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $83.23M, a 2598.70% increase year-over-year.
- Nuvation Bio Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $41.87M, a 633.06% increase year-over-year.
- Nuvation Bio Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $13.12M, a 1704.68% increase year-over-year.
- Nuvation Bio Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $62.90M, a 698.96% increase from fiscal 2024.
- Nuvation Bio Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $7.87M.
- Nuvation Bio Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.69M 10-Q · filed 2026-08-06 | $114.92M 10-Q · filed 2026-08-06 | $156.78M derived: sum of 3 quarters · filed 2026-08-06 | $169.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $83.23M 10-Q · filed 2026-05-04 | $125.09M derived: sum of 2 quarters · filed 2026-05-04 | $138.21M derived: sum of 3 quarters · filed 2026-05-04 | $143.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $41.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $54.98M derived: sum of 2 quarters · filed 2026-03-02 | $59.82M derived: sum of 3 quarters · filed 2026-08-06 | $62.90M 10-K · filed 2026-03-02 |
| 2025-09-30 | $13.12M 10-Q · filed 2025-11-03 | $17.95M derived: sum of 2 quarters · filed 2026-08-06 | $21.04M 10-Q · filed 2025-11-03 | $26.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.83M 10-Q · filed 2026-08-06 | $7.92M 10-Q · filed 2026-08-06 | $13.63M derived: sum of 3 quarters · filed 2026-08-06 | $14.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.08M 10-Q · filed 2026-05-04 | $8.79M derived: sum of 2 quarters · filed 2026-05-04 | $9.52M derived: sum of 3 quarters · filed 2026-05-04 | $10.96M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $5.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.44M derived: sum of 2 quarters · filed 2026-03-02 | $7.87M derived: sum of 3 quarters · filed 2026-03-02 | $7.87M 10-K · filed 2026-03-02 |
| 2024-09-30 | $727.00K 10-Q · filed 2025-11-03 | $2.16M derived: sum of 2 quarters · filed 2025-11-03 | $2.16M 10-Q · filed 2025-11-03 | $2.16M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $1.44M 10-Q · filed 2025-08-07 | $1.44M 10-Q · filed 2025-08-07 | $1.44M derived: sum of 3 quarters · filed 2025-08-07 | $1.44M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-05-07 | $0.00 derived: sum of 3 quarters · filed 2025-05-07 | $0.00 derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 derived: sum of 3 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-05 | $0.00 10-Q · filed 2024-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |